Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
13 mai 2024 08h00 HE
|
Alvotech
REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...
Alvotech kynnir uppgjör fyrsta ársfjórðungs 2024 22. maí nk. kl. 12 að íslenskum tíma
13 mai 2024 08h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrsta ársfjórðungs 2024 eftir lokun markaða í Bandaríkjunum, þriðjudaginn 21. maí nk. Þá mun Alvotech halda kynningarfund fyrir...
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
13 mai 2024 08h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
Alvotech tekur þátt í heilbrigðisráðstefnu BofA Securities í Bandaríkjunum
02 mai 2024 07h15 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að félagið taki þátt í árlegri heilbrigðisráðstefnu BofA Securities, sem haldin verður dagana 14. – 15. maí í Las Vegas, Nevadafylki Bandaríkjanna. Fulltrúar úr...
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
02 mai 2024 07h15 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be...
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
02 mai 2024 07h15 HE
|
Alvotech
REYKJAVIK, Iceland, May 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30 avr. 2024 04h00 HE
|
Alvotech
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S....
Alvotech semur við Quallent Pharmaceuticals um markaðssetningu á hliðstæðu við Humira í Bandaríkjunum
30 avr. 2024 04h00 HE
|
Alvotech
Alvotech mun framleiða líftæknilyfjahliðstæðu sína í háum styrk með útskiptileika við Humira (adalimumab) fyrir Quallent Pharmaceuticals, dótturfélag Cigna Alvotech (NASDAQ: ALVO) tilkynnti í dag...
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30 avr. 2024 04h00 HE
|
Alvotech
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S....
Alvotech kynnir jákvæða niðurstöðu rannsóknar á sjúklingum sem sýnir sömu klínísku virkni líftæknilyfjahliðstæðunnar AVT05 og Simponi® (golimumab)
24 avr. 2024 04h00 HE
|
Alvotech
Meginendapunktur rannsóknarinnar var uppfylltur, þegar borin var saman klínísk virkni, öryggi og ónæmingarverkun AVT05 og Simponi (golimumab) í sjúklingum með meðallagi alvarlega eða alvarlega...